

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Cortendo AB

Serial No. : 10/019,613 Authorized Officer: Not Yet Assigned

Filed : December 28, 2001 Group Art Unit: Not Yet Assigned

For : USE OF CORTISOL ANTAGONISTS IN THE TREATMENT
OF HEART FAILURE

DUPLICATE
INFORMATION
DISCLOSURE
STATEMENT

I hereby certify that this paper is being deposited with the United States
Postal Service as Express Mail No. EU206387892US addressed to:
Commissioner for Patents, Washington, DC 20231

March 21, 2002

Date of Deposit

Rochelle K. Seide
Attorney Name

Rochelle K. Seide
Signature

32,200

PTO Registration No.

March 21, 2002

Date of Signature

Hon. Commissioner for Patents and Trademarks
United States Patent and Trademark Office
Washington DC 20231

Sir:

Pursuant to the provisions of 37 C.F.R. §§ 1.56, 1.97(b) and 1.98, Applicants
hereby submit a duplicate copy of the Information Disclosure Statement and PTO Form

1449, which were filed concurrently with the original application on December 28, 2001, but with which the citations contained therein were inadvertently omitted. Applicants respectfully request that the citations relating to the above-mentioned application listed herein be considered by the Examiner and made of record in the U.S. Patent and Trademark Office. The citations are listed in the accompanying Duplicate PTO Form 1449 and copies of the citations are enclosed.

1. International Patent Application No. PCT/FR98/02302 by Antonov for "Use of antifungal agents for treating scleroses" filed 27 October 1998 and published as WO 00/24402 on 4 May, 2000.
2. International Patent Application No. PCT/SE99/01713 by Uvnäs-Moberg *et al.* for "Use of substances with oxytocin activity in order to create cell regeneration" filed 27 September 1999 and published as WO 00/18424 on 6 April 2000.
3. Faggiano P, D'Aloia A, Gualeni A, Giordano A. Hemodynamic profile of submaximal constant workload exercise in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. *Am J Cardiol* 1998 Feb 15;81(4):437-442.
4. Ganiats TG, Browner DK, Dittrich HC. Comparison of Quality of Well-Being scale and NYHA functional status classification in patients with atrial fibrillation. New York Heart Association. *Am Heart J* 1998 May;135(5 Pt 1):819-824.

5. Scheuer DA, Mifflin SW. Chronic cortisone treatment increases myocardial infarct size in rats with ischemia-reperfusion injury. *Am J Physiol* 1997 Jun;272(6 Pt 2):R2017-2024.
6. Spitz IM, Bardin CW. Mifepristone (RU 486)--a modulator of progestin and glucocorticoid action. *N Engl J Med* 1993 Aug 5;329(6):404-412.
7. Rotstein DM, Kertesz DJ, Walker KA, Swinney DC. Stereoisomers of ketoconazole: preparation and biological activity. *J Med Chem* 1992 Jul 24;35(15):2818-2825.
8. Dvortsin GF. Use of a synthetic opioid for the reversal of stress-induced damage of the myocardium and gastric mucosa in severe thermal trauma [In Russian]. *Kardiologiia* 1989 Sep;29(9):81-83.
9. Aggermaes H, Kirkegaard C, Magelund G. The effect of sodium valproate on serum cortisol levels in healthy subjects and depressed patients. *Acta Psychiatr Scand* 1988 Feb;77(2):170-174.
10. Slowinska-Srzednicka J, Zgliczynski S, Soszynski P, Pucilowska J, Wierzbicki M, Jeske W. Effect of clonidine on beta-endorphin, ACTH and cortisol secretion in essential hypertension and obesity. *Eur J Clin Pharmacol* 1988;35(2):115-121.
11. Legros JJ, Chiodera P, Geenen V, von Frenckell R. Confirmation of the inhibitory influence of exogenous oxytocin on cortisol and ACTH in man: evidence of reproducibility. *Acta Endocrinol (Copenh)* 1987 Mar;114(3):345-349.

12. United States Patent No. 4,603,141 by Giles for "Oral Clonidine Treatment of Congestive Heart Failure" issued July 29, 1986.
13. Loose DS, Stover EP, Feldman D. Ketoconazole binds to glucocorticoid receptors and exhibits glucocorticoid antagonist activity in cultured cells. J Clin Invest 1983 Jul;72(1):404-408.
14. Stubbs WA, Delitala G, Jones A, Jeffcoate WJ, Edwards CR, Ratter SJ, Besser GM, Bloom SR, Alberti KG. Hormonal and metabolic responses to an enkephalin analogue in normal man. Lancet 1978 Dec 9;2(8102):1225-1227.

The submission of this Duplicate Information Disclosure Statement does not represent that a search has been made or that no better art exists and does not constitute an admission that any of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

This Duplicate Information Disclosure Statement is being filed, Applicants believe, before the mailing date of a first Office Action on the merits for the above-referenced application. Therefore, Applicants do not believe that any fee is due connection with the filing of this Statement. However, if any fee is due or overpayment made, the Commissioner is authorized to charge any such fee, and to credit any overpayment, to our Deposit Account No. 02-4377. Two copies of this communication are enclosed.

Respectfully submitted,

BAKER BOTTS L.L.P.

A handwritten signature in cursive script, reading "Rochelle K. Seide". The signature is written in black ink and is positioned above a horizontal line.

Rochelle K. Seide, Ph.D.
Patent Office Reg. No. 32,200

Attorney for Applicants
(212) 408-2626

Enclosures